Study Provides First Preclinical Evidence of a Bispecific Trifunctional Antibody–Induced Anti-Tumor Vaccination Effect in Neuroblastoma


Recent research found that the disialoganglioside 2–directed bispecific trifunctional antibody has 2 binding sites which allows for a mitigated T-cell anti-tumor response.

A research team in Berlin has published what they say is the first evidence that a disialoganglioside 2–directed bispecific trifunctional antibody (trAb) – a molecule engineered to have two antigen-binding sites, enabling it to simultaneously bind to a tumor-associated antigen and a T-cell receptor (TCR) complex CD3 – can mediate TCR–independent T-cell anti-tumor responses and induce an anti-tumor vaccination effect that prolonged survival in a tumor-challenged murine model of neuroblastoma.

The study shows for the first time that the SUREK trAb “induces a tumor-specific immunological memory, which was completely absent after tumor vaccination alone,” write Felix Zirngibl, MD, and colleagues at the Berlin Institute of Health. “The production of tumor-directed antibodies was increased by a combination therapy with anti-Pd-1 checkpoint inhibition.” The study appears in the January issue of Frontiers in Immunology.

Novel therapies are needed for neuroblastoma, the most common extracranial solid tumor in children with overall survival in recurrent disease that ranges from 2% to 15%, the authors write. “Combining tumor vaccination and SUREK trAb treatment with additional checkpoint inhibitors might further improve anti-tumor effector function and could translate into the clinic as a prophylactic therapy option for children with minimal residual disease.”


Ivasko SM, Anders K, Grunewald L, et al. Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model. Front Immunol. 2023;13:1023206. Published Jan 9, 2023. doi:10.3389/fimmu.2022.1023206

Recent Videos
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Related Content